Snapshot from Aug 08, 2026 at 07:00 UTC. For live data and tracking: View Live
Business earnings call

Coherus Q2 2026 results release

Analysis based on 8 articles · First reported Jul 22, 2026 · Last updated Jul 22, 2026

Sentiment
0
Attention
0
Articles
8
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The announcement is a routine scheduling event with minimal direct market impact. Investors will await the actual results on August 5 for any material changes to the company's financial outlook.

biotechnology pharmaceuticals

Coherus Oncology, Inc. announced that its second quarter 2026 financial results will be released on August 5, 2026, followed by a conference call and webcast with management to discuss the results and provide a business update. The company is a commercial-stage oncology firm with an approved PD-1 inhibitor, LOQTORZI, and a pipeline of clinical candidates.

10 Coherus BioSciences announced Q2 results release
stock
Coherus is the subject of the event; it announced the timing of its Q2 2026 earnings release and conference call.
Importance 100.0 Sentiment 0.0
per
Carrie Graham is the Vice President of Investor Relations & Advocacy at Coherus, listed as a contact for investors.
Importance 10.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.